MannKind's reverse stock split gave investors the blues.
News & Analysis: MannKind
The biopharma's reverse split isn't a hit with investors.
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.
A handful of positive developments caused shares to rally.
What does MannKind's update this week mean for investors?
Shares fell hard after management announced that a reverse stock split might be in the cards.
MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?
MannKind's dreadful 2016 may have marked the beginning of the end of this struggling drugmaker.
Arena Pharmaceuticals, MannKind Corp., and Dynavax Technologies Corp. may all be worth selling for tax purposes right now.
Which of these diabetes-focused companies is the better bet for new money today?